Andy Pike

1.2k total citations
24 papers, 447 citations indexed

About

Andy Pike is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Andy Pike has authored 24 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in Andy Pike's work include Protein Degradation and Inhibitors (7 papers), Ubiquitin and proteasome pathways (5 papers) and PARP inhibition in cancer therapy (4 papers). Andy Pike is often cited by papers focused on Protein Degradation and Inhibitors (7 papers), Ubiquitin and proteasome pathways (5 papers) and PARP inhibition in cancer therapy (4 papers). Andy Pike collaborates with scholars based in United Kingdom, United States and Singapore. Andy Pike's co-authors include Beth Williamson, Scott Martin, Stephanie Harlfinger, Dermot F. McGinnity, John G. Pearce, Giske Ursin, Donna Shoupe, Malcolm C. Pike, Yuri R. Parisky and Darcy Spicer and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Andy Pike

23 papers receiving 432 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andy Pike United Kingdom 9 250 203 78 54 43 24 447
Buğra Özer Türkiye 8 237 0.9× 58 0.3× 30 0.4× 25 0.5× 49 1.1× 16 346
Yuhong Sun China 11 177 0.7× 140 0.7× 42 0.5× 18 0.3× 86 2.0× 23 421
Cheng Du China 12 235 0.9× 96 0.5× 55 0.7× 27 0.5× 83 1.9× 21 370
John Dixon United Kingdom 8 180 0.7× 74 0.4× 55 0.7× 54 1.0× 72 1.7× 11 508
Bo Mu China 13 316 1.3× 180 0.9× 58 0.7× 10 0.2× 158 3.7× 26 562
Nicolas Borisov Russia 18 404 1.6× 96 0.5× 128 1.6× 18 0.3× 182 4.2× 31 659
Martine B.W. Prinsen Netherlands 11 270 1.1× 151 0.7× 80 1.0× 36 0.7× 65 1.5× 19 456
Chengcan Yang China 11 263 1.1× 74 0.4× 34 0.4× 31 0.6× 48 1.1× 14 368
Sharon L. Freshour United States 2 339 1.4× 60 0.3× 120 1.5× 12 0.2× 103 2.4× 3 585

Countries citing papers authored by Andy Pike

Since Specialization
Citations

This map shows the geographic impact of Andy Pike's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Pike with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Pike more than expected).

Fields of papers citing papers by Andy Pike

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Pike. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Pike. The network helps show where Andy Pike may publish in the future.

Co-authorship network of co-authors of Andy Pike

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Pike. A scholar is included among the top collaborators of Andy Pike based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Pike. Andy Pike is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pike, Andy, et al.. (2025). Lessons learned in linking PROTACs from discovery to the clinic. Nature Reviews Chemistry. 10(2). 117–132. 1 indexed citations
2.
Caron, Giulia, Gauri Deshmukh, Andy Pike, et al.. (2025). Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization towards orally available bifunctional protein degraders. Expert Opinion on Drug Discovery. 20(3). 373–389. 6 indexed citations
3.
Bagal, Sharan K., Peter C. Astles, C. R. Diène, et al.. (2024). Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry. 67(14). 11732–11750. 5 indexed citations
4.
Schade, Markus, James S. Scott, Thomas G. Hayhow, et al.. (2024). Structural and Physicochemical Features of Oral PROTACs. Journal of Medicinal Chemistry. 67(15). 13106–13116. 32 indexed citations
5.
Barlaam, Bernard, C. R. Diène, Eva M. Lenz, et al.. (2024). The Role of Intramolecular Reactions and Chemical Degradation in the Apparent Biotransformation Pathways of a Series of SYK Inhibitors. Drug Metabolism and Disposition. 52(7). 626–633.
6.
Humphreys, Sara C., David O. Nettleton, Colin Phipps, et al.. (2023). Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders. Drug Metabolism and Disposition. 51(7). 792–803. 29 indexed citations
7.
Staniszewska, Anna D., Domenic Pilger, Giuditta Illuzzi, et al.. (2022). DDDR-01. AZD9574 IS A NOVEL, BRAIN PENETRANT PARP-1 SELECTIVE INHIBITOR WITH ACTIVITY IN AN INTRACRANIAL XENOGRAFT MODEL OF TRIPLE NEGATIVE BREAST CARCINOMA WITH HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY. Neuro-Oncology. 24(Supplement_7). vii98–vii98. 2 indexed citations
8.
Pike, Andy, et al.. (2021). Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs. Drug Metabolism and Disposition. 49(9). 736–742. 3 indexed citations
9.
Gill, Sonja J., Ruth S. MacDonald, Carmen Pin, et al.. (2021). Abstract 1374: The novel PARP1-selective inhibitor AZD5305 has reduced hematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models. Cancer Research. 81(13_Supplement). 1374–1374. 2 indexed citations
10.
Staniszewska, Anna D., Andy Pike, Christine Fazenbaker, et al.. (2021). Abstract 1270: The novel PARP1-selective inhibitor, AZD5305, is efficacious as monotherapy and in combination with standard of care chemotherapy in the in vivo preclinical models. Cancer Research. 81(13_Supplement). 1270–1270. 3 indexed citations
11.
Pike, Andy, Beth Williamson, Stephanie Harlfinger, Scott Martin, & Dermot F. McGinnity. (2020). Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discovery Today. 25(10). 1793–1800. 155 indexed citations
12.
Barlaam, Bernard, Scott Boiko, Scott Boyd, et al.. (2020). Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(22). 127523–127523. 3 indexed citations
13.
Srivastava, Abhishek, Andy Pike, Beth Williamson, & Katherine S. Fenner. (2020). A Novel Method for Preventing Non-specific Binding in Equilibrium Dialysis Assays Using Solutol® as an Additive. Journal of Pharmaceutical Sciences. 110(3). 1412–1417. 13 indexed citations
14.
Pike, Andy, Richard Storer, Robert M. Owen, et al.. (2016). The design, synthesis and evaluation of low molecular weight acidic sulfonamides as URAT1 inhibitors for the treatment of gout. MedChemComm. 7(8). 1572–1579. 10 indexed citations
15.
Atack, John, Andy Pike, Susan M. Cook, et al.. (2006). RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708. Drug Metabolism and Disposition. 34(5). 887–893. 19 indexed citations
16.
Atack, John, Andy Pike, George Marshall, et al.. (2006). The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagoclone. Neuropharmacology. 50(6). 677–689. 14 indexed citations
17.
Spicer, Darcy, Giske Ursin, Yuri R. Parisky, et al.. (1994). Changes in Mammographic Densities Induced by a Hormonal Contraceptive Designed to Reduce Breast Cancer Risk. JNCI Journal of the National Cancer Institute. 86(6). 431–436. 115 indexed citations
18.
19.
Greene, James M., et al.. (1986). Some new methods for preparing 2,3‐ and 3,4‐diaminopyridines. Journal of Heterocyclic Chemistry. 23(3). 669–672. 12 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Buğra Özer Breakdown of academic impact, for papers by Yuhong Sun Breakdown of academic impact, for papers by Cheng Du Breakdown of academic impact, for papers by John Dixon Breakdown of academic impact, for papers by Bo Mu Breakdown of academic impact, for papers by Nicolas Borisov Breakdown of academic impact, for papers by Martine B.W. Prinsen Breakdown of academic impact, for papers by Chengcan Yang Breakdown of academic impact, for papers by Sharon L. Freshour
Rankless by CCL
2026